1. Home
  2. UTF vs BEAM Comparison

UTF vs BEAM Comparison

Compare UTF & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$27.69

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.69

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
BEAM
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.0B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
UTF
BEAM
Price
$27.69
$27.69
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$50.75
AVG Volume (30 Days)
268.3K
2.7M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
N/A
$24,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
33.33
52 Week Low
$23.42
$15.60
52 Week High
$27.99
$38.26

Technical Indicators

Market Signals
Indicator
UTF
BEAM
Relative Strength Index (RSI) 58.28 34.36
Support Level $26.54 $26.96
Resistance Level $27.90 $29.68
Average True Range (ATR) 0.31 2.45
MACD 0.01 -0.95
Stochastic Oscillator 62.50 5.82

Price Performance

Historical Comparison
UTF
BEAM

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: